Keywords: Anika Therapeutics, Hyalograft C autograft, Europe, MAA withdrawn, Surgical repair

Anika Therapeutics withdraws EU marketing application for Hyalograft C autograft

Article | 27 February 2013

Print This

The European Medicines Agency says it has been formally notified by the European subsidiary of USA-based Anika Therapeutics (Nasdaq: ANIK) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in